Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

5-5-5 Adaptive Bridging Radiation Therapy (ABRT) for Relapsed/Refractory B-cell Lymphoma Prior to CAR T-cell Therapy

NCT06004167 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT06004167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06004167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
5-5-5 Adaptive Bridging Radiation Therapy (ABRT) for Relapsed/Refractory B-cell Lymphoma Prior to CAR T-cell Therapy
Lead sponsor
Massachusetts General Hospital
Phase
Not applicable
Overall status
Completed
Start date
January 14, 2024
Completion date
December 1, 2024
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, follicular lymphoma, high-grade b-cell lymphoma, lymphoma, b-cell, mantle cell lymphoma, mediastinal large b-cell lymphoma, refractory lymphoma, relapsed cancer